Background There is no effective therapy for COVID-19. Hydroxychloroquine (HCQ) and
chloroquine (CQ) have been used for its treatment but their safety and efficacy remain uncertain…

The first consensus report of the working party of the Asian Pacific Association for the Study
of the Liver (APASL) set up in 2004 on acute-on-chronic liver failure (ACLF) was published in …

Background and Aim Liver fibrosis is an established determinant of prognosis and therapy
in chronic hepatitis B ( CHB ). The role of fibroscan in assessing fibrosis in CHB remains …

Background Frequency of hepatocellular carcinoma ( HCC ) in hepatic venous outflow tract
obstruction ( HVOTO ) is unclear and risk factors in HVOTO associated with HCC are …

Therapeutics aimed at treating non-alcoholic fatty liver disease (NAFLD) target the pathogenic
process from deranged metabolism leading to steatosis to cell stress and death, leading …

Background and Aim There is a paucity of data on the clinical presentations and outcomes
of Corona Virus Disease-19 (COVID-19) in patients with underlying liver disease. We aimed …

… i told her about the SukarnoShalimar connection, and she remembered that the name of the
… on the cool night air like Shalimar’. but the idea of Shalimar would never be enough for me: i …

Hepatitis E virus (HEV) causes acute hepatitis in many parts of the world including Asia, Africa
and Latin America. Though self-limiting in normal individuals, it results in ~30% mortality …

Antituberculosis therapy (ATT)–associated acute liver failure (ATT‐ALF) is the commonest
drug‐induced ALF in South Asia. Prospective studies on ATT‐ALF are lacking. The current …

Ammonia is thought to be central to the pathogenesis of hepatic encephalopathy (HE), but its
prognostic role in patients with cirrhosis and acute decompensation is unknown. The aims …